Edwards Lifesciences Corp(EW)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #455 of 2,879 stocksTOP 25%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
EW Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Edwards Lifesciences Corp (EW), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores EW at 67.6/100 on a 32-signal composite quality model, placing it at rank #455 of 2,879 stocks — the top 25% of the AI-ranked universe. EW scores in the top quartile across balance sheet strength (86.4), revenue scale (81.1), profitability (80.1). Areas of concern include institutional flow (4.3) and earnings quality (5.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 36.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Edwards Lifesciences Corp reports quarterly revenue of $1.6B, net income of $380.7M, free cash flow of $-21.1M. Top institutional holders of EW by reported 13-F value include BlackRock,, STATE STREET, WELLINGTON MANAGEMENT GROUP LLP, based on the most recent SEC filings. EW trades on the NYSE exchange and files with the SEC under CIK 1099800. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EW daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Edwards Lifesciences Corp directly from SEC EDGAR. Edwards Lifesciences Corp's 13F Pro composite quality score has ranged between 8 and 78 since 2021, currently 67.6 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.
What's Driving EW's Business? Latest 10-Q Breakdown
AI-extracted from Edwards Lifesciences Corp's 10-Q filed 2026-05-06 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Edwards Lifesciences reported Q1 2026 net sales of $1.65B, up 16.7% YoY, driven by TAVR growth of 14.4% and TMTT surging 51.9%, though a $123.6M impairment charge and litigation costs pressured earnings.
Biggest Revenue Drivers
Total revenue: $1,648.6M+16.7% YoY
Higher sales of Edwards SAPIEN platform, primarily SAPIEN 3 Ultra RESILIA valve in US, Europe, and Japan; $32M benefit from Euro strengthening.
Higher sales of INSPIRIS RESILIA aortic valve, MITRIS RESILIA valve, and KONECT RESILIA tissue valved conduit in US and Europe.
Higher sales of PASCAL transcatheter edge-to-edge repair system and EVOQUE tricuspid valve replacement system in US and Europe.
Largest Expense Items
Increased investments in implantable heart failure management and advanced technology innovation.
Margins: Gross profit margin as a percentage of sales declined despite 16.7% revenue growth, primarily driven by a 30 basis point headwind from foreign currency rate fluctuations (including settlement of hedging contracts) and additional manufacturing expenses from new therapy expansion. Operating income margin improved modestly from operational leverage, offset by higher litigation expenses and impairment charges.
Watch Items from the Filing
- IRS transfer pricing dispute: company received Draft NOPAs for 2018–2020 proposing $2.1B in additional US taxable income adjustments; final NOPAs expected by Q2 2026 with potential material impact.
- $123.6M impairment charge on one variable interest entity investment in Q1 2026 reflects concentration risk in venture/equity investments; total non-marketable equity securities at $185.8M.
- Litigation expenses surged to $37.1M in Q1 (from $10.9M YoY); multiple pending patent and shareholder derivative lawsuits; accrued liability reduced to $57.3M from $146.2M at year-end.
- Acquired Autus Valve in February 2026 for $128.9M cash with contingent consideration up to $132.5M on regulatory/sales milestones; total future acquisition payments could reach $332.5M.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Revenue
Q1 2026
$1.6B
Net Income
Q1 2026
$380.7M
Free Cash Flow
Q1 2026
$-21.1M
D/E Ratio
Q1 2026
0.06
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+11.5% YoYNet Income
-74.3% YoYOperating Income
-8.3% YoYEPS (Diluted)
-73.7% YoYTotal Assets
+4.9% YoYTotal Debt
+0.1% YoYOp. Cash Flow
+194.2% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $6.07B +11.5% | $5.44B +8.6% | $5.01B +12.2% | $4.46B +1.8% | $4.39B +0.9% | $4.35B |
| Net Income | $1.07B -74.3% | $4.17B +197.7% | $1.40B -7.9% | $1.52B | — | — |
| Operating Income | $1.26B -8.3% | $1.38B +5.3% | $1.31B -12.6% | $1.50B +66.9% | $897.6M -21.7% | $1.15B |
| EPS (Diluted) | $1.83 -73.7% | $6.97 +203.0% | $2.30 -5.7% | $2.44 +87.7% | $1.30 +137.8% | $0.55 |
| Total Assets | $13.70B +4.9% | $13.06B +39.4% | $9.36B +12.9% | $8.29B +14.6% | $7.24B +11.5% | $6.49B |
| Total Debt | $598.3M +0.1% | $597.7M +0.1% | $597.0M +0.1% | $596.3M +0.2% | $595.0M +0.1% | $594.4M |
| Operating Cash Flow | $1.60B +194.2% | $542.3M -39.5% | $895.8M -26.5% | $1.22B +15.5% | $1.05B -10.9% | $1.18B |
AI Insight: EW Financial Trends
Revenue growth accelerating to 3.9% YoY in Q1 2026, but operating margin compression and collapsing Q4 2025 net income signal execution headwinds.
• Revenue grew 16.7% from Q2 2024 ($1,135M) to Q1 2026 ($1,649M), with Q1 2026 showing 3.9% YoY growth versus Q1 2025.
• Operating income margin deteriorated from 29.3% in Q2 2024 to 9.6% in Q4 2025, recovering only to 29.0% in Q1 2026.
• Operating cash flow swung to $451M in Q4 2025 and $44M in Q1 2026 after negative $128M in Q4 2024, showing volatile conversion.
⚠ Net income collapsed to $91M in Q4 2025 (6.3% margin) from $358M in Q1 2025, indicating significant non-operating headwinds or one-time charges.
⚠ Total debt stable at $598M throughout period; equity rose 39% from $7,437M to $10,328M, strengthening balance sheet resilience.
AI Insight: EW Ratio Trends
Q1 2026 margins and ROIC rebounded sharply after Q4 2025 collapse, but TTM profitability metrics remain well below 2024 baseline.
• Operating margin surged to 29.0% in Q1 2026 from 9.6% in Q4 2025; NPM jumped to 23.1% from 5.8%.
• ROIC recovered to 17.5% in Q1 2026, highest since Q2 2024's 16.6%, reversing Q4 2025's 5.5% low.
• TTM OpMargin at 21.4% and ROIC at 12.3% remain 7–4 percentage points below Q2 2024 levels.
⚠ Q4 2025 saw severe margin compression (9.6% OpMargin, 5.8% NPM); verify if one-time or structural.
⚠ Q3 2025 ROE/ROA spikes (128.7%, 94.7%) are annualization artifacts; actual Q3 profitability was weak.
Get alerted when EW's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Edwards Lifesciences Corp including:
Top Institutional Holders of EW
BlackRock, Inc.
$4.2B52,590,933 shSTATE STREET CORP
$2.1B26,296,399 shWELLINGTON MANAGEMENT GROUP LLP
$1.8B22,011,101 shBank of New York Mellon Corp
$1.3B16,737,548 shFMR LLC
$1.2B14,503,770 shGEODE CAPITAL MANAGEMENT, LLC
$1.0B13,133,777 shJENNISON ASSOCIATES LLC
$1.0B13,066,274 shDZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt
$1.0B12,811,902 shNinety One UK Ltd
$992.7M12,396,143 shMORGAN STANLEY
$565.4M7,060,876 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $4.2B | 52,590,933 |
| STATE STREET CORP | $2.1B | 26,296,399 |
| WELLINGTON MANAGEMENT GROUP LLP | $1.8B | 22,011,101 |
| Bank of New York Mellon Corp | $1.3B | 16,737,548 |
| FMR LLC | $1.2B | 14,503,770 |
| GEODE CAPITAL MANAGEMENT, LLC | $1.0B | 13,133,777 |
| JENNISON ASSOCIATES LLC | $1.0B | 13,066,274 |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt | $1.0B | 12,811,902 |
| Ninety One UK Ltd | $992.7M | 12,396,143 |
| MORGAN STANLEY | $565.4M | 7,060,876 |
More Healthcare Companies
View all Healthcare →Put EW on your watchlist
Track score changes the day Edwards Lifesciences Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is EW a good stock to buy?
13F Pro's AI-powered analysis of Edwards Lifesciences Corp (EW) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EW are available on the EW stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own EW?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EW. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Edwards Lifesciences Corp's investment landscape.